This site is intended for healthcare professionals
News

NICE does not recommend Saxenda as a treatment for obesity. - Novo Nordisk

Read time: 1 mins
Published:27th Jan 2020
The National Institute for Health and Care Excellence (NICE) has rejected Saxenda ( liraglutide) from Novo Nordisk for use on the NHS, citing its list price and lack of long-term efficacy data in recently published draft guidance . Saxenda showed clinical effectiveness in preventing the development of Type 2 diabetes but NICE argued that "its long-term effectiveness, particularly on the risk of cardiovascular disease, is unknown." NICE was also not impressed with Saxenda's price—listed at £196.20 ($256.43) for 5 x 6 mg/ml 3-ml (18 mg) pre-filled pens—despite a confidential discount from Novo.
Condition: Obesity
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.